NASDAQ:ADPT Adaptive Biotechnologies Q2 2026 Earnings Report $20.82 -0.68 (-3.16%) Closing price 07/7/2026 04:00 PM EasternExtended Trading$20.90 +0.09 (+0.41%) As of 07/7/2026 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Adaptive Biotechnologies EPS ResultsActual EPSN/AConsensus EPS -$0.13Beat/MissN/AOne Year Ago EPSN/AAdaptive Biotechnologies Revenue ResultsActual RevenueN/AExpected Revenue$65.81 millionBeat/MissN/AYoY Revenue GrowthN/AAdaptive Biotechnologies Announcement DetailsQuarterQ2 2026Date8/4/2026TimeAfter Market ClosesConference Call DateTuesday, August 4, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Adaptive Biotechnologies Earnings HeadlinesAdaptive Biotechnologies (NASDAQ:ADPT) Insider Susan Bobulsky Sells 487 Shares of StockJuly 7 at 9:24 AM | americanbankingnews.comInsider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells 51,004 SharesJuly 7 at 8:38 AM | americanbankingnews.com“By July 30, Elon Musk’s Prophecy Will Fulfill Itself”Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI breakthrough they call 'M.A.G.I.' will collide with a rare market pattern by July 30. That pattern carries a 100% historical track record. The last time it triggered, early investors had a chance to turn $10,000 into as much as $350,000 in roughly 12 months. | Brownstone Research (Ad)Adaptive Biotechnologies (NASDAQ:ADPT) Insider Francis Lo Sells 44,838 SharesJuly 7 at 8:38 AM | americanbankingnews.comAdaptive Biotechnologies Corporation (NASDAQ:ADPT) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 4, 2026 | americanbankingnews.comSharon Benzeno Sells 154,768 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) StockJuly 2, 2026 | americanbankingnews.comSee More Adaptive Biotechnologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adaptive Biotechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adaptive Biotechnologies and other key companies, straight to your email. Email Address About Adaptive BiotechnologiesAdaptive Biotechnologies (NASDAQ:ADPT) is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development. The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners. Adaptive also develops T-cell receptor (TCR) discovery services to support the discovery and development of novel TCR-based therapeutics. Its offerings span research services, clinical diagnostics, and collaborative programs with leading drug developers to advance immune-driven medicine. Founded in 2009 and headquartered in Seattle, Washington, Adaptive Biotechnologies maintains research and operations facilities in North America and Europe. The company collaborates with global technology and life sciences organizations, including a strategic partnership with Microsoft to apply machine learning to immune data. Adaptive’s platform has been utilized in oncology, autoimmune and infectious disease research across multiple continents. Adaptive Biotechnologies is led by co-founder and CEO Chad Robins, under whose guidance the firm continues to expand its molecular profiling capabilities and build a world-class immune medicine business.View Adaptive Biotechnologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles GE Vernova’s Power Surge Turns the Grid Into an AI Trade2 Short Squeezes for Summer Speculation: What the Bears Are Getting WrongBig Beautiful Boycott: Can It Really Hurt Coca-Cola, Amazon, and Kraft Heinz Stocks?Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term InvestorsMarketBeat Week in Review – 06/29 - 07/03Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponVisa’s Open USD Push Puts Circle’s Stablecoin Moat Under Pressure Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
